Revised May 2013
NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction.
This charge has two critical components. The first is the strategic support and conduct of research across a broad range of disciplines. The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.
Funding decisions will be based primarily on programmatic priority of the Institute and scientific merit of the application. NIDA continues to give additional consideration to first-time R01 investigators and Early Stage Investigators (by NIH definition).
Information regarding FY 2013 NIH Extramural Financial Operations can be found at:
- Resources for FY 2013: http://grants1.nih.gov/grants/financial/index.htm#Res13
- NIH Fiscal Policy for Grant Awards – FY 2013: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-064.html
- FY 2013 NRSA Stipends: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-033.html
The National Institute on Drug Abuse (NIDA) has established the following funding policy for FY 2013:
NIDA may reduce competing awards from IRG recommended levels in order to increase the number of awards issued.
- Inflationary increases for future year commitments will be discontinued for all competing research grant awards issued in FY 2013.
- In general renewal grants should not increase by more than 10% over the prior year’s award.
Non-Competing Continuation Awards
Consistent with overall NIH policy every effort will be made to keep the average size of awards constant at FY 2012 levels.
- Non-competing awards will be issued without cost of living/inflationary adjustments in FY 2013.
- FY 2013 awards that have already been issued will be revised to adjust the award level.
- R13 and RSDAs continuation awards will be funded at committed, including co-funds.
- Modular and Non-modular continuation awards will be funded at approximately 96% of committed levels, including co-funds.
- NSRAs (Fs and Ts) will be issued at the FY 2012 stipend levels.
NIDA will continue to support the:
- NIH Pathway to Independence Awards (K99/R00) (http://grants.nih.gov/grants/guide/pa-files/PA-11-197.html) to maintain new and talented NIH-supported independent investigators.
Search for Funding
Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.